Article
Tracking early lung cancer metastatic dissemination in TRACERx using ctDNA.
Nature - 1 Apr 2023
Abbosh Christopher, Frankell Alexander M, Harrison Thomas, Kisistok Judit, Garnett Aaron, Johnson Laura, Veeriah Selvaraju, Moreau Mike, Chesh Adrian, Chaunzwa Tafadzwa L, Weiss Jakob, Schroeder Morgan R, Ward Sophia, Grigoriadis Kristiana, Shahpurwalla Aamir, Litchfield Kevin, Puttick Clare, Biswas Dhruva, Karasaki Takahiro, Black James R M, Martínez-Ruiz Carlos, Bakir Maise Al, Pich Oriol, Watkins Thomas B K, Lim Emilia L, Huebner Ariana, Moore David A, Godin-Heymann Nadia, L'Hernault Anne, Bye Hannah, Odell Aaron, Roberts Paula, Gomes Fabio, Patel Akshay J, Manzano Elizabeth, Hiley Crispin T, Carey Nicolas, Riley Joan, Cook Daniel E, Hodgson Darren, Stetson Daniel, Barrett J Carl, Kortlever Roderik M, Evan Gerard I, Hackshaw Allan, Daber Robert D, Shaw Jacqui A, Aerts Hugo J W L, Licon Abel, Stahl Josh, Jamal-Hanjani Mariam, Birkbak Nicolai J, McGranahan Nicholas, Swanton Charles
Abstract excerpt
Circulating tumour DNA (ctDNA) can be used to detect and profile residual tumour cells persisting after curative intent therapy1. The study of large patient cohorts incorporating longitudinal plasma sampling and extended follow-up is required to determine the role of ctDNA as a phylogenetic biomarker of relapse in early-stage non-small-cell lung cancer (NSCLC). Here we developed ctDNA methods tracking a median of...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.